Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.07 · 8-K

EBR Systems, Inc.

EBRCZOTCEQUITYCurrent

Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On August 18, 2026 (U.S. Pacific time), EBR Systems, Inc. (the “ Company ”) held a Special Meeting of Stockholders (the “Special Meeting”) virtually via live webcast. At the Special Meeting, the Company’s stockholders voted on the three proposals set forth below.…

Filed Aug 20, 2026Accepted Aug 20, 2026, 3:00 PM EDTCIK 1347123Accession 0001214659-26-010643
Share

Company context

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

Current securities

Historical securities (1)

Recent company filings

  1. 10-Q filingNov 9, 2026
  2. S-8 filingAug 24, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsAug 24, 2026
  4. 10-Q filingAug 11, 2026
  5. DEFA14A filingJul 9, 2026

Disclosure sections

Items 5.07

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 18, 2026 (U.S. Pacific time), EBR Systems, Inc. (the “ Company ”) held a Special Meeting of Stockholders (the “Special Meeting”) virtually via live webcast. At the Special Meeting, the Company’s stockholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in the Company’s Proxy Statement filed with the Securities and Exchange Commission on July 9, 2026 (the “Proxy Statement”). Proposal 1 - Ratification of Security Issuances. The Company’s stockholders approved the ratification of the issuance of 77,352,890 CDIs (equivalent to 7,735,289 shares of common stock) at an issue price of A$0.38 per CDI, on terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of Australian Securities Exchange (“ASX”) Listing Rule 7.4. The results of the vote were: For Against Abstain Broker Non-Vote Uncast * ───────────────────────────────────────────────────────────────────────────── 34,724,458 485,633 1,750,135 0 0 * Represents shares underlying votes that were not cast held by holders subject to a voting exclusion on the matter or that were disregarded, pursuant to ASX Listing Rule 14.11.1, as further described in the Proxy Statement Proposal 2 - Approval of Security Issuances. The Company’s stockholders approved the issuance of 92,105,270 CDIs (equivalent to 9,210,527 shares of common stock) at an issue price of A$0.38 per CDI to certain clients of BCP3 Pty Ltd, an associate of Dr. Chris Nave (a non-executive director of the Company), on terms and conditions set out in the Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11. The results of the vote were: For Against Abstain Broker Non-Vote Uncast * ─────────────────────────────────────────────────────────────────────────────── 24,746,794 512,726 1,119,243 0 10,581,462 Proposal 3 - Adjournment of Special Meeting. The Company’s stockholders approved the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Proposal 1 or Proposal 2. The results of the vote were: For Against Abstain Broker Non-Vote Uncast ───────────────────────────────────────────────────────────────────────── 36,960,227 0 0 0 0 No other matters were submitted for stockholder action at the Special Meeting.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.